Supplementary Online Content

Gage BF, Bass AR, Lin H, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. *JAMA*. doi:10.1001/jama.2017.11469

eTable 1. Demographic and Clinical Characteristics of Randomized Participants
eTable 2. Number of Participants with Secondary Endpoints from Randomization until Post-op Day 30
eFigure. Kaplan-Meier Plot Showing the Time to a Therapeutic INR in Participants Randomized to Clinically Guided Dosing or Genotype-Guided Dosing

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Demographic and Clinical Characteristics of Randomized Participants

	N (%)	N (%)	p-value
	Did not get Intervention*	**Received Intervention**	
Characteristics	**(n=53)**	**(n=1597)**	
Age in years, mean (SD)	72.0 (5.1)	72.1 (5.4)	0.94
Body mass index (kg/m^2), mean (SD)	30.6 (6.2)	29.2 (5.5)	0.11
Baseline INR, mean (SD)	1.03 (0.06)	1.01 (0.06)	0.017
Indication			0.0012
Hip Replacement	24 (45.3)	406 (25.4)	
Knee Replacement	29 (54.7)	1191 (74.6)	
Randomization Arm			0.30
Genotype-guided	23 (43.4)	808 (50.6)	
Clinically-guided	30 (56.6)	789 (49.4)	
Target INR			0.0497
1.8	19 (35.9)	804 (50.3)	
2.5	34 (64.1)	793 (49.7)	
Female	31 (58.5)	1018 (63.7)	0.43
Race			0.71
African American	4 (7.6)	102 (6.4)	
Caucasian	48 (90.6)	1454 (91.1)	
Asian or Indian Subcontinent	0 (0.0)	29 (1.8)	
Other or unknown	1 (1.9)	12 (0.8)	
Hispanic	0 (0.0)	42 (2.6)	0.64
Smoker	5 (9.4)	54 (3.4)	0.038
Diabetes	11 (20.8)	221 (13.8)	0.15
Liver Disease	0 (0.0)	12 (0.75)	> 0.99

*53 patients did not get the intervention: 22 did not have arthroplasty, 15 withdrew, 7 were prescribed thromboprophylaxis other than warfarin, 6 developed an exclusion, and 3 were found to be ineligible.

eTable 2. Number of Participants with Secondary Endpoints from Randomization until Post-op Day 30

Secondary Endpoints	Genotype-Guided Group N = 808 N (%)	Clinical Group N = 789 N (%)	P-value
Adverse Event (AE)*	**123 (15.2)**	**120 (15.2)**	**0.99**
Serious AE	46 (5.7)	56 (7.1)	0.25
Non-serious AE	84 (10.4)	75 (9.5)	0.55
Non-Major bleed	**83 (10.3)**	**83 (10.5)**	**0.87**
Clinically relevant bleed	56 (6.9)	66 (8.4)	0.28
Not significant minor bleed	43 (5.3)	36 (4.6)	0.48
Cardiovascular Event	**10 (1.2)**	**13 (1.6)**	**0.49**
Myocardial infarction	3 (0.4)	3 (0.4)	1.00
Stroke	1 (0.1)	0 (0.0)	1.00
Atrial fibrillation	6 (0.7)	10 (1.3)	0.29
Infection†	**50 (6.2)**	**48 (6.1)**	**0.93**
Serious AE infection	15 (1.9)	12 (1.5)	0.60
AE infection	47 (5.8)	42 (5.3)	0.67
Infection by location†	**50 (6.2)**	**48 (6.1)**	**0.93**
Joint infection (hip or knee)	5 (0.6)	1 (0.1)	0.22
Wound drainage or cellulitis	23 (2.9)	24 (3.0)	0.82
Other Infection	25 (3.1)	36 (3.3)	0.82

* Number of participants with one or more adverse events (AE) other than major bleeds, venous thromboembolism, or elevated international normalized ratio values. Participants who had multiple events are counted only once in the bolded rows. For example, a patient who had both post-op myocardial infarction and atrial fibrillation is counted only once in the bolded row titled, "Cardiovascular Event."

† Stitch abscesses without sequelae are not included as infections.

eFigure. Kaplan-Meier Plot Showing the Time to a Therapeutic INR in Participants Randomized to Clinically Guided Dosing or Genotype-Guided Dosing

Participants had at least 1 INR measured. For a target of 2.5, INR values in the range of [2-3] were considered therapeutic; for a target of 1.8, INRs in the range of [1.5-2.1] were therapeutic.